
FACTMATE AIDS



CFB/EAK

24th May 1983.

Dr. J.D. Colledge, The Surgery, Hamstreet, ASHFORD, Kent,

Dear Dr. Colledge,

re: FACTORATE (Antihaemophilic Fraction B.P.)

We acknowledge receipt of your letter of the 10th May, asking whether we are able to supply non-American material.

Presumably your letter has been prompted by the enormous publicity given to the subject of AIDS and the possibility that you have a haemophilia patient under your care at the present time.

Much of the publicity, as you know, has been erotive and to a great extent, inaccurrate. Conversely, there have been a number of well informed authoritive publications, which have done much to place things in their true prospective and to allay many of the fears and the concern felt by the UK patient receiving regular blood component therapy, and in particular, the UK haemophiliac.

In particular, the recent letter from Professor A. Dloom which was included in the most recent edition of the Haemophilia Society Bulletin, together with an authorative overview of the AIDS situation by Dr. Kernoff, will we hope help to further reassure the UK haemophiliac and those charged with his care. In case you have not already seen it, I enclose a copy of the letter and the bulletin.

In answer to your specific question, the Armour Pharmaceutical Company through its subsidiary, Plasma Alliance, operates 16 Centres located in the mid-west and south-east portions of the United States. Non of these Centres are located in the AIDS high-incidence areas of the Country (New York City, Miami, San Francisco, Los Angeles), nor is plasma used in the manufacture of clotting factor products obtained from facilities located in these areas. Furthermore, no plasma is obtained from collection facilities located outside of the United States.

Despite the fact that there is little evidence to associate plasma component therapy with the transmission of AIDS, Arnour, through its affiliate organisation, Plasma Alliance, has had programmes in operation for several months, which have been designed to help prevent the utilisation of plasma obtained from members of high-risk groups associated with AIDS in the production of clotting factor concentrates.

ARMOUR002085

We are firmly committed to providing safe and effective products to the medical profession, and will continue to devote our energies and resources to the problems associated with AIDS and haemophilia treatment and will continue our efforts to resolve them.

We do hope that the foregoing is of interest to you, and please do not hesitate to contact us again should you require any further information or assistance.

Yours sincerely,

· ~ ~ 1

GRO-C

C.R. Bishop, Lanager, Plasma Division.

Bechust 10X

0 Mayel by T. N. D.F. 8/6/83.

cc: D.H. Ferguson Master Day File

ARMOUR002086

ARMO0000252_0002